In the context of FLT3-mutated AML, for instance, by examining pre- and post-therapy treatment samples of patients with FLT3 mutations on gilteritinib (selective FLT3 kinase inhibitor), an emergent outgrowth of clones with RAS mutations and suppression of clones with FLT3-ITD mutations was observed. Here, FLT3 is linked to acute myeloid leukemia.